Quality of life and viral control after HIV long-acting injections
Part of Immune system & allergy, Infections clinical trials.
This study looks at how the long-acting injectable treatment for HIV affects your quality of life and how well it keeps the virus under control. If you've already completed the injections, you'll be asked to complete questionnaires about your experiences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a clinical diagnosis of HIV (you are HIV positive).
- You must have already completed the long-acting injectable treatment (Cabotegravir and Rilpivirine shots).
- You must agree to fill out questionnaires about your quality of life and viral control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people living with HIV feel about switching to a new injectable treatment called cabotegravir and rilpivirine. It aims to understand real-life experiences and quality of life after making the switch.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
This study follows people with HIV who are starting or have recently started a treatment using two long-acting medications, cabotegravir and lenacapavir. It aims to see how well this combination works in real life, which could help improve care for others.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
Hear when a new AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.